Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02190695 · ClinicalTrials.gov registry record · Phase 2
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT02190695 is a Phase 2 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 92 participants.
The verdict
NCT02190695, a Phase 2 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study is to find a new way to treat Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). All the drugs are used to treat AML and MDS but are not usually combined together. The investigators are looking at both the safety and Efficacy of each combination.
Interventions
- DRUG Carboplatin
- DRUG Decitabine
- DRUG Arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-04-01 |
| Est. Completion | 2020-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02190695
The ClinicalTrials.gov registry entry for NCT02190695 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02190695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02190695 about?
NCT02190695 is a clinical study titled "Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS". The purpose of this study is to find a new way to treat Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). All the drugs are used to treat AML and MDS but are not usually combined together. The investigators are looking at both the safety and Eff...
What is the current status of trial NCT02190695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2013-04-01. Estimated completion is 2020-04-16.
What interventions are being tested in trial NCT02190695?
The interventions under investigation include: Carboplatin (DRUG), Decitabine (DRUG), Arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT02190695?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.